Replimune Group (REPL) Price & Analysis

Compare

436 Followers

REPL Stock Chart & Stats

Day’s Range― - ―

52-Week Range$2.68 - $17.00

Previous CloseN/A

Volume95.41K

Average Volume (3M)3.90M

Market Cap

$365.30M

Enterprise Value$523.17M

Total Cash (Recent Filing)$403.34M

Total Debt (Recent Filing)$76.33M

Price to Earnings (P/E)―

Beta0.37

Next Earnings

Oct 30, 2025

EPS Estimate

-0.75

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.95

Shares Outstanding78,055,850

10 Day Avg. Volume3,874,978

30 Day Avg. Volume3,897,132

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap1.43

Enterprise Value/Revenue355.42

Enterprise Value/Gross Profit-184.93

Enterprise Value/Ebitda-1.94

Forecast

1Y Price Target

$3.83

Price Target Upside-16.19% Downside

Rating ConsensusHold

Number of Analyst Covering9

Bulls Say, Bears Say

Bulls Say

Clinical DataThe data for RP1 in advanced melanoma is compelling, with significant response rates and no major safety concerns.

Community SupportThere is strong support from the physician and patient community for RP1, which could lead to positive regulatory changes.

EarningsREPL ended F1Q with $403.3M in cash and cash equivalents, guiding to having sufficient cash runway to fund operations into 4Q26.

Bears Say

Clinical Trial ConcernsThe FDA did not view the IGNYTE trial as an adequate and well-controlled clinical investigation, raising concerns about its effectiveness.

FDA ResponseThe FDA issued a Complete Response Letter regarding the Biologics License Application for RP1, which was viewed as a negative surprise.

Regulatory ChallengesThe regulatory path forward for RP1 is unclear and potentially challenging, making accelerated approval seem less likely.

Replimune Group News

Intel downgraded, Tesla upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

20d ago

CVX

MET

Replimune downgraded to Underweight from Neutral at JPMorgan

JPMorgan downgraded Replimune (REPL) to Underweight from Neutral without a price target The regulatory path forward for RP1...

20d ago

REPL

Replimune says ‘committed’ to working with FDA to determine path forward for RP1

Replimune (REPL) Group announced that the company completed a Type A meeting with the U.S. Food and Drug...

21d ago

REPL

Replimune Group Completes FDA Meeting on RP1 Application

Replimune Group ( ($REPL) ) has issued an announcement. On September 18, 2025, Replimune Group announced the completion...

21d ago

REPL

Replimune Group Schedules Crucial FDA Meeting for RP1

Replimune Group ( ($REPL) ) has provided an update. On September 3, 2025, Replimune Group held its annual...

1M ago

REPL

REPL Lawsuit Alert! Class Action Lawsuit Against Replimune Group

A class action lawsuit was filed against Replimune Group ($REPL) by Levi & Korsinsky on July 24, 2025. The plaintiffs (shareholders)...

1M ago

BMY

REPL

Replimune announces Type A meeting scheduled with FDA

Replimune (REPL) Groupy announced that a Type A meeting with the U.S. Food and Drug Administration, FDA, has...

1M ago

REPL

Video: Nvidia, AMD said to pay U.S. 15% of revenue from China chip sales

The Fly has brought its to-the-moment stock market reporting to YouTube! Subscribe if you want to know how...

2M ago

ALB

Replimune Group Reports Increased Losses Amid Rising R&D Costs

Replimune Group ( ($REPL) ) has released its Q1 earnings. Here is a breakdown of the information Replimune...

2M ago

REPL

Replimune sees cash runway into 4Q26

As of June 30, 2025, cash, cash equivalents and short-term investments were $403.3 million, as compared to $483.8...

2M ago

REPL

Replimune reports Q1 EPS (95c), consensus (81c)

“Based on the compelling clinical data and safety profile generated to date with RP1 in the IGNYTE study,...

2M ago

REPL

Why Is Replimune Stock (NASDAQ:REPL) Exploding?

Shares of Replimune Group ($REPL) surged over 100% on Wednesday to $7.55. The surge came after the sudden...

2M ago

REPL

Replimune upgraded to Overweight at Cantor after Prasad leaves FDA

As previously reported, Cantor Fitzgerald analyst Li Watsek upgraded Replimune (REPL) to Overweight from Neutral following news that...

2M ago

REPL

Replimune upgraded to Overweight from Neutral at Cantor Fitzgerald

Cantor Fitzgerald upgraded Replimune (REPL) to Overweight from Neutral. Published first on TheFly – the ultimate source for...

2M ago

REPL

REPL FAQ

What was Replimune Group Inc’s price range in the past 12 months?

Replimune Group Inc lowest stock price was $2.68 and its highest was $17.00 in the past 12 months.

What is Replimune Group Inc’s market cap?

Replimune Group Inc’s market cap is $365.30M.

When is Replimune Group Inc’s upcoming earnings report date?

Replimune Group Inc’s upcoming earnings report date is Oct 30, 2025 which is in 21 days.

How were Replimune Group Inc’s earnings last quarter?

Replimune Group Inc released its earnings results on Aug 07, 2025. The company reported -$0.95 earnings per share for the quarter, missing the consensus estimate of -$0.794 by -$0.156.

Is Replimune Group Inc overvalued?

According to Wall Street analysts Replimune Group Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Replimune Group Inc pay dividends?

Replimune Group Inc does not currently pay dividends.

What is Replimune Group Inc’s EPS estimate?

Replimune Group Inc’s EPS estimate is -0.75.

How many shares outstanding does Replimune Group Inc have?

Replimune Group Inc has 78,055,850 shares outstanding.

What happened to Replimune Group Inc’s price movement after its last earnings report?

Replimune Group Inc reported an EPS of -$0.95 in its last earnings report, missing expectations of -$0.794. Following the earnings report the stock price went down -0.364%.

Which hedge fund is a major shareholder of Replimune Group Inc?

Currently, no hedge funds are holding shares in REPL

Replimune Group Stock Smart Score

Underperform

Fundamentals

Return on Equity

-73.44%

Trailing 12-Months

Asset Growth

-12.24%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Replimune Group Inc

Replimune Group, Inc. (REPL) is a biotechnology company focused on developing oncolytic immunotherapies for the treatment of cancer. The company operates in the healthcare sector, specifically within the biopharmaceutical industry. Replimune's core products are based on its proprietary Immulytic platform, which is designed to enhance the systemic anti-tumor immune response by using genetically engineered viruses to selectively infect and kill cancer cells while sparing normal tissue.

Replimune Group (REPL) Earnings & Revenues

Historic Earnings Reports

REPL Earnings Call

Q4 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call provided a positive outlook, highlighting significant regulatory achievements, strong commercial readiness, and financial stability. However, the increase in net loss and operational expenses presents challenges. The overall sentiment is optimistic about RP1's potential launch and market adoption.View all REPL earnings summaries

REPL Stock 12 Month Forecast

Average Price Target

$3.83

▼(-16.19% Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","14":"$14","4.25":"$4.25","7.5":"$7.5","10.75":"$10.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.83,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$3.83</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,4.25,7.5,10.75,14],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.9,6.061538461538462,6.223076923076923,6.384615384615385,6.546153846153846,6.707692307692308,6.86923076923077,7.030769230769231,7.1923076923076925,7.353846153846154,7.515384615384615,7.676923076923077,7.838461538461539,{"y":8,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.9,5.7407692307692315,5.581538461538462,5.422307692307693,5.263076923076923,5.103846153846154,4.944615384615385,4.785384615384616,4.626153846153846,4.466923076923077,4.3076923076923075,4.148461538461539,3.9892307692307694,{"y":3.83,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.9,5.6000000000000005,5.300000000000001,5,4.7,4.4,4.1,3.8,3.5,3.2,2.9,2.5999999999999996,2.3,{"y":2,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.36,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.22,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.17,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.9,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.55,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.11,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.98,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.4,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.64,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.57,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.15,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.6,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.9,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >